Fluorine-18/lutenium-177 theranostic - Fuzionaire Theranostics
Alternative Names: 18F/177Lu theranostic pairLatest Information Update: 11 Aug 2023
At a glance
- Originator Fuzionaire Theranostics
- Class Antineoplastics; Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters; Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Prostate cancer
Most Recent Events
- 04 Aug 2023 Preclinical trials in Prostate cancer (Diagnosis) in USA (Parenteral), prior to August 2023 (Fuzionaire Theranostics pipeline, August 2023)
- 04 Aug 2023 Preclinical trials in Prostate cancer in USA (Parenteral), prior to August 2023 (Fuzionaire Theranostics pipeline, August 2023)
- 31 Jul 2023 Fuzionaire Diagnostics is now called Fuzionaire Theranostics